Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tribenoside is a small molecule vasoprotective and anti-inflammatory drug primarily used for the treatment of hemorrhoids and venous circulation disorders such as varicose veins and phlebitis[1][2][3][4]. It exhibits mild anti-inflammatory, analgesic, wound-healing, antitoxic, fibrinolysis-promoting, membrane-stabilizing, and venotropic properties[6][8]. Tribenoside acts by reducing vascular permeability and causing vasoconstriction. Mechanistically, it antagonizes inflammatory mediators including histamine, serotonin (5-HT), bradykinin and others[3]. It also stimulates laminin α5 production and laminin-332 deposition to support basement membrane repair during wound healing[1]. Unlike corticosteroids or NSAIDs it does not adversely affect the gastrointestinal tract or immune system[6][8]. Tribenoside is often formulated in combination with lidocaine for topical use in hemorrhoid management under brand names such as Procto-Glyvenol[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tribenoside.